ClinicalTrials.Veeva

Menu
N

Novel Research | Bellaire Location

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-279
Ianalumab
Ozanimod

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 7 total trials

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling
Crohn's Disease
Drug: TAK-279
Drug: Placebo

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical...

Enrolling
Ulcerative Colitis
Drug: TAK-279
Drug: Placebo

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants wi...

Enrolling
Colitis, Ulcerative
Drug: Ozanimod

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of...

Enrolling
Systemic Lupus Erythematosus
Drug: placebo
Drug: ianalumab
Status recently updated

The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injectio...

Not yet enrolling
Enrolling
Sjögrens Disease
Systemic Lupus Erythematosus
Biological: VAY736 2ml AI
Biological: VAY736 1ml PFS

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Novartis logo
Takeda logo
Bristol-Myers Squibb (BMS) logo
Janssen (J&J Innovative Medicine) logo
Novo Nordisk logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems